Hemogenyx Pharmaceuticals PLC Announces Further re. Grant of Options
LONDON, UK / ACCESSWIRE / September 22, 2020 / On 21 August 2020, the Company announced that the Directors had granted the Company’s co-founder and CEO Dr Vladislav Sandler options over a total of 5,000,000 ordinary shares of 1p each in the capital of the Company (“Share Options”). The Directors have now resolved to adjust the exercise price of the Share Options to 9p to reflect the Company’s share price at the time of the grant. All other details regarding the grant of the Share Options remain the same.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
peter.redmond@hemogenyx.com |
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Soltan Tagiev |
|
|
Peterhouse Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
Notification and public disclosure of transactions by persons discharging managerial responsibilities (“PDMR”) and persons closely associated with them (“PCA”):
|
1. |
Details of PDMR/person closely associated with them |
|||||
|
a) |
Name |
Dr Vladislav Sandler |
||||
|
b) |
Position/status |
CEO, Executive Director |
||||
|
c) |
Initial notification/ |
Amendment to prior notification no. 00117904 |
||||
|
2. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument |
Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc |
||||
|
b) |
Nature of the transaction |
Grant of options |
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information – Aggregated volume – Price |
|
||||
|
e) |
Date of the transaction |
20/08/2020 |
||||
|
f) |
Place of the transaction |
Outside of a trading venue |
||||
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com:
https://www.accesswire.com/607236/Hemogenyx-Pharmaceuticals-PLC-Announces-Further-re-Grant-of-Options
